Stoke Therapeutics (STOK) and Biogen (BIIB) announced the publication of data from studies of the investigational medicine zorevunersen. This includes results from two completed Phase 1/2a and ongoing open-label extension studies that demonstrate the potential for disease modification in people living with Dravet syndrome. The data showed substantial and durable reductions in seizures and improvements across multiple measures of cognition and behavior that began in the Phase 1/2a treatment period and continued through three additional years of treatment in the OLEs.
Barry Ticho, Chief Medical Officer of Stoke Therapeutics, said: "By targeting the underlying genetic cause of the disease, zorevunersen has the potential to be the first disease-modifying medicine for the treatment of Dravet syndrome. We look forward to the results of our Phase 3 EMPEROR study expected in mid-2027."
At last close on NasdaqGS, Stoke shares were trading at $34.42, up 1.89%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.